CS
KRYS icon

Credit Suisse’s Krystal Biotech KRYS Stock Holding History

Credit Suisse’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$57.3M Sell
321,946
-152,538
-32% -$21.2M 0.05% 335
2023
Q4 		$58.9M Buy
474,484
+240,863
+103% +$26.7M 0.06% 341
2023
Q3 		$27.1M Sell
233,621
-233,567
-50% -$28.5M 0.03% 564
2023
Q2 		$54.8M Sell
467,188
-165,636
-26% -$16.9M 0.05% 376
2023
Q1 		$50.7M Sell
632,824
-50,056
-7% -$3.93M 0.05% 397
2022
Q4 		$54.1M Buy
682,880
+4,410
+0.6% +$327K 0.06% 363
2022
Q3 		$47.3M Sell
678,470
-24,433
-3% -$1.77M 0.05% 390
2022
Q2 		$46.2M Sell
702,903
-54,956
-7% -$3.42M 0.05% 413
2022
Q1 		$50.4M Buy
757,859
+4,179
+0.6% +$261K 0.04% 440
2021
Q4 		$52.7M Sell
753,680
-18,274
-2% -$1.06M 0.03% 614
2021
Q3 		$40.3M Buy
771,954
+5,629
+0.7% +$333K 0.02% 732
2021
Q2 		$52.1M Sell
766,325
-13,075
-2% -$913K 0.03% 662
2021
Q1 		$60M Buy
779,400
+3,872
+0.5% +$282K 0.03% 625
2020
Q4 		$46.5M Buy
775,528
+1,274
+0.2% +$63.6K 0.02% 750
2020
Q3 		$33.3M Buy
774,254
+91,710
+13% +$3.98M 0.02% 782
2020
Q2 		$28.3M Buy
682,544
+102,108
+18% +$4.91M 0.02% 779
2020
Q1 		$25.1M Buy
580,436
+299,818
+107% +$15.7M 0.02% 716
2019
Q4 		$15.5M Buy
280,618
+212,981
+315% +$10.4M 0.01% 1174
2019
Q3 		$2.35M Sell
67,637
-1,575
-2% -$70.4K ﹤0.01% 2350
2019
Q2 		$2.79M Buy
+69,212
New +$2.26M ﹤0.01% 2201

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Credit Suisse's KRYS Position: Q1 2024 in Review

Credit Suisse reduced its Krystal Biotech (KRYS) stake by 32% in Q1 2024, selling an estimated $21.2M and leaving 321,946 shares worth $57.3M. The position accounts for 0.05% of the portfolio, ranked #335.

Credit Suisse first reported a position in KRYS in Q2 2019 and has held it in 20 quarters since. The position peaked at $60M in Q1 2021. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Credit Suisse held 321,946 shares of Krystal Biotech worth $57.3M as of Q1 2024.
  • Credit Suisse sold 152,538 Krystal Biotech shares in Q1 2024, an estimated $21.2M.
  • Krystal Biotech made up 0.05% of Credit Suisse's portfolio in Q1 2024, its #335 holding.
  • Credit Suisse first reported a position in Krystal Biotech in Q2 2019 and has held it in 20 quarters since.
  • Credit Suisse's Krystal Biotech position peaked at $60M in Q1 2021.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.